The Food and Drug Administration Feb. 5 released an alert notifying patients of a safety concern using diabetes devices such as continuous glucose monitors, insulin pumps and automated insulin dosing systems that rely on a smartphone for delivering alerts. The agency said it received medical device reports in which users reported alerts were not being delivered or heard in situations where the users thought they configured the alerts to be delivered. Some instances may have contributed to serious harm, including severe hypoglycemia, severe hyperglycemia, diabetic ketoacidosis and death.   

The FDA issued recommendations for users and said it is working with diabetes-related medical device manufacturers to ensure that smartphone alert configurations are evaluated prior to use. It is also working with manufacturers to ensure settings for smartphones and mobile medical applications are continuously tested and that updates are communicated quickly and clearly to users.

Headline
The Federal Trade Commission announced Sept. 9 that it rescinded its 2021 policy statement that extended applicability of its health breach notification rule…
Headline
Clint Pridgen, vice president of business development and hospital strategy at Laerdal Medical, explores the future of healthcare simulation, including data-…
Headline
In this conversation, John Riggi, AHA national advisor for cybersecurity and risk, and Scott Gee, AHA deputy national advisor for cybersecurity and risk, break…
Headline
The AHA has released a fact sheet explaining how artificial intelligence tools help alleviate administrative burden for providers, particularly in areas such…
Headline
The Food and Drug Administration is seeking public feedback on a discussion paper released today on potential regulatory approaches for generative artificial…
Headline
The Centers for Medicare & Medicaid Services yesterday announced the launch of QualTech, a new event created to identify innovative technology that…